** Shares of biotech firm IGM Biosciences IGMS.O slump ~69% to $1.92 premarket
** On Thursday, IGMS said it is halting further development of 2 drugs, imvotamab and IGM-2644, that were being tested for immunity-related diseases
** Early-stage trail data shows imvotamab is not effective enough in depleting B cells, a type of white blood cells, for rheumatoid arthritis and systemic lupus erythematosus - CEO Mary Beth Harler
** Co also plans to lay off about 73% of its employees
** As of Dec. 31, 2023, co had 224 full-time employees - SEC filing
** Brokerage RBC Capital Markets notes IGMS's preclinical collaboration with Sanofi SNY.O SASY.PA for undisclosed I&I (immunology and inflammation) targets but does not expect it "to drive near-term value"
** RBC downgrades stock to "sector perform" from "outperform" and cuts PT to $1.50 from $20
** At least three other brokerages also downgrade stock and cut PT
** IGMS declined ~30% in 2024
(Reporting by Kamal Choudhury in Bengaluru)
((Kamal.Choudhury@thomsonreuters.com))
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。